Malvern Panalytical, a company providing advanced analysis and services solutions for the pharma drug product development, as well as services and solutions for other industries, has today announced its acquisition of Creoptix AG, a specialist bioanalysis sensor company. The acquisition forms a critical part of Malvern Panalytical’s strategy to expand its capabilities in support of drug

Creoptix, a Switzerland-based company focused on next-generation bioanalytical instruments, has launched waveRAPID (Repeated Analyte Pulses of Increasing Duration), a novel, label-free kinetic measurement method that is said to be faster than traditional kinetics. The company developed the Creoptix WAVEsystem to enable molecular interactions to be studied in real time, aimimng to revolutionise drug discovery. By